CorMedix Inc.
Last updated September 27, 2026
Organization details
- Legal name
- CorMedix Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- CRMD
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001410098
Board of directors
-
Alan W. Dunton · DirectorSince 2023
-
Gregory Scott Duncan · DirectorSince 2023
-
Janet Dillione · DirectorSince 2023
-
Joseph Todisco · Director · Chief Executive OfficerSince 2023
-
Myron Kaplan · DirectorSince 2023
-
Paulo F. Costa · DirectorSince 2023
-
Robert A. Stewart · DirectorSince 2023
-
Steven W. Lefkowitz · DirectorSince 2023
Chief executives
Joseph Todisco
· Chief Executive Officer
Dates unknown
Board connections
2 of this board's directors also sit on 3 other boards.
- via Gregory Scott Duncan
- via Alan W. Dunton
- via Alan W. Dunton
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 10, 2024 | Joseph Todisco Director, Officer (Chief Executive Officer) | Shares withheld for tax | −26,982 | $5.17 | $139,497 |
| Mar 13, 2024 | Joseph Todisco Director, Officer (Chief Executive Officer) | Open-market purchase | +13,561 | $3.74 | $50,718 |
| Jan 12, 2024 | Masson-Hurlburt Elizabeth Officer (EVP, Head of Clinical Ops.) | Grant or award | +50,000 | — | — |
| Jan 12, 2024 | David Matthew T Officer (Chief Financial Officer) | Grant or award | +50,000 | — | — |
| Jan 12, 2024 | Mistry Erin Officer (Chief Commercial Officer) | Grant or award | +50,000 | — | — |
| Jan 12, 2024 | Joseph Todisco Director, Officer (Chief Executive Officer) | Grant or award | +133,333 | — | — |
| Jan 12, 2024 | Masson-Hurlburt Elizabeth Officer (EVP, Head of Clinical Ops.) | Shares withheld for tax | −4,603 | $3.47 | $15,972 |
| Jan 12, 2024 | David Matthew T Officer (Chief Financial Officer) | Shares withheld for tax | −5,216 | $3.47 | $18,100 |
| Jan 12, 2024 | Mistry Erin Officer (Chief Commercial Officer) | Shares withheld for tax | −4,389 | $3.47 | $15,230 |
| Jan 12, 2024 | Joseph Todisco Director, Officer (Chief Executive Officer) | Shares withheld for tax | −13,781 | $3.47 | $47,820 |
| Dec 15, 2023 | Alan W. Dunton Director | Open-market purchase | +3,000 | $3.30 | $9,900 |
| Dec 14, 2023 | Alan W. Dunton Director | Open-market purchase | +3,000 | $3.45 | $10,350 |
| Dec 12, 2023 | Zelnick Kaufman Beth Officer (Chief Legal Officer) | Grant or award | +50,000 | — | — |
| Nov 17, 2023 | Mistry Erin Officer (Chief Commercial Officer) | Open-market purchase | +1,000 | $4.00 | $4,000 |
| Nov 16, 2023 | Steven W. Lefkowitz Director | Option exercise | +15,000 | $2.25 | $33,750 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.